Moving Receptor Redirected Adoptive Cell Therapy Toward Fine Tuning of Antitumor Responses

REFERENCES

• Dudley ME, Yang JC, Sherry R, Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008; 26:5233–5239.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA. Cell transfer immunotherapy for metastatic solid cancer—what clinicians need to know. Nat Rev Clin Oncol 2011;8:577–585.
   PubMed Web of Science ®Google Scholar
• Weber J, Atkins M, Hwu P, on behalf of the Immunotherapy Task Force of the NCI Investigational Drug Steering Committee. White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy. Clin Cancer Res 2011;17:1664–1673.
   PubMed Web of Science ®Google Scholar
• Joncker NT, Marloie M-A, Chernysheva A, Lonchay C, Cuff S, Klijanienko J, Sigal-Zafrani B, Vincent-Salomon A, Sastre X, Lantz O. Antigen-independent accumulation of activated effector/memory T lymphocytes into human and murine tumors. Int J Cancer 2006;118:1205–1214.
   Google Scholar
• Johnson LA, Morgan RA, Dudley ME, Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009;114:535–546.
   PubMed Web of Science ®Google Scholar
• Robbins PF, Morgan RA, Feldman SA, Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 2011;29:917–924.
   PubMed Web of Science ®Google Scholar
• Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci 1993;90:720–724.
   PubMed Web of Science ®Google Scholar
• Kowolik CM, Topp MS, Gonzalez S, CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res 2006;66:10995–11004.
   PubMed Web of Science ®Google Scholar
• Carpenito C, Milone MC, Hassan R, Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci 2009;106:3360–3365.
   PubMed Web of Science ®Google Scholar
• Milone MC, Fish JD, Carpenito C, Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther 2009;17:1453–1464.
   PubMed Web of Science ®Google Scholar
• Kalos M, Levine BL, Porter DL, T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011;3:95ra73–95ra73.
   PubMed Web of Science ®Google Scholar
• Porter DL, Levine BL, Kalos M, Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia. N Engl J Med 2011;365:725–733.
   PubMed Web of Science ®Google Scholar
• Brentjens RJ, Davila ML, Riviere I, CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 2013;5:177ra38.
   PubMed Web of Science ®Google Scholar
• Grupp SA, Kalos M, Barrett D, Chimeric antigen receptor–modified T cells for acute lymphoid leukemia. N Engl J Med 2013;368:1509–1518.
   PubMed Web of Science ®Google Scholar
• Davila ML, Riviere I, Wang X, Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 2014;6:224ra25–224ra25.
   PubMed Web of Science ®Google Scholar
• Eggermont AMM, Kroemer G, Zitvogel L. Immunotherapy and the concept of a clinical cure. Eur J Cancer 2013;49:2965–2967.
   PubMed Web of Science ®Google Scholar
• Dudley ME. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298:850–854.
   PubMed Web of Science ®Google Scholar
• Yeh S, Karne NK, Kerkar SP, Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma. Ophthalmology 2009;116:981–989.
   PubMed Web of Science ®Google Scholar
• Parkhurst MR, Yang JC, Langan RC, T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther 2011;19:620–626.
   PubMed Web of Science ®Google Scholar
• Morgan RA, Chinnasamy N, Abate-Daga D, Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother 2013;36:133–151.
   PubMed Web of Science ®Google Scholar
• Linette GP, Stadtmauer EA, Maus MV, Cardiovascular toxicity and titin cross-reactivity of affinity enhanced T cells in myeloma and melanoma. Blood 2013;122:863–871.
   PubMed Web of Science ®Google Scholar
• Kong S, Sengupta S, Tyler B, Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptor–modified T cells. Clin Cancer Res 2012;18:5949–5960.
   PubMed Web of Science ®Google Scholar
• Kochenderfer JN, Yu Z, Frasheri D, Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood 2010;116:3875–3886.
   PubMed Web of Science ®Google Scholar
• Lamers CHJ, Sleijfer S, Vulto AG, Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol 2006;24:e20–e22.
   PubMedGoogle Scholar
• Morgan RA, Yang JC, Kitano M, Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ErbB2. Mol Ther 2010;18:843–851.
   PubMed Web of Science ®Google Scholar
• Brentjens R, Yeh R, Bernal Y, Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol Ther 2010;18:666–668.
   PubMed Web of Science ®Google Scholar
• Palaiologou M, Delladetsima I, Tiniakos D. CD138 (syndecan-1) expression in health and disease. Histol Histopathol 2014;29:177–189.
   PubMed Web of Science ®Google Scholar
• Goodyear O, Agathanggelou A, Novitzky-Basso I, Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. Blood 2010;116:1908–1918.
   PubMed Web of Science ®Google Scholar
• Barrett DM, Teachey DT, Grupp SA. Toxicity management for patients receiving novel T-cell engaging therapies. Curr Opin Pediatr 2014;26:43–49.
   PubMed Web of Science ®Google Scholar
• Xu X-J, Tang Y-M. Cytokine release syndrome in cancer immunotherapy with chimeric antigen receptor engineered T cells. Cancer Lett 2014;343:172–178.
   PubMed Web of Science ®Google Scholar
• Duarte S, Carle G, Faneca H, Suicide gene therapy in cancer: where do we stand now? Cancer Lett 2012;324:160–170.
   PubMed Web of Science ®Google Scholar
• Serafini M, Bonamino M, Golay J, Introna M. Elongation factor 1 (EF1alpha) promoter in a lentiviral backbone improves expression of the CD20 suicide gene in primary T lymphocytes allowing efficient rituximab-mediated lysis. Haematologica 2004;89:86–95.
   Google Scholar
• Serafini M, Manganini M, Borleri G, Characterization of CD20-transduced T lymphocytes as an alternative suicide gene therapy approach for the treatment of graft-versus-host disease. Hum Gene Ther 2004;15:63–76.
   PubMed Web of Science ®Google Scholar
• Straathof KC. An inducible caspase 9 safety switch for T-cell therapy. Blood 2005;105:4247–4254.
   PubMed Web of Science ®Google Scholar
• Casucci M, Nicolis di Robilant B, Falcone L, CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma. Blood 2013;122:3461–3472.
   PubMed Web of Science ®Google Scholar
• Di Stasi A, Tey SK, Dotti G, Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 2011;365:1673–1683.
   PubMed Web of Science ®Google Scholar
• Marin V, Cribioli E, Philip B, Comparison of different suicide-gene strategies for the safety improvement of genetically manipulated T cells. Hum Gene Ther Methods 2012;23:376–386.
   PubMed Web of Science ®Google Scholar
• Morgan RA, Dudley ME, Wunderlich JR, Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006;314:126–129.
   PubMed Web of Science ®Google Scholar
• Alexander-Miller MA, Leggatt GR, Berzofsky JA. Selective expansion of high-or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc Natl Acad Sci 1996;93:4102–4107.
   PubMed Web of Science ®Google Scholar
• Zeh HJ, Perry-Lalley D, Dudley ME, High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol 1999;162:989–994.
   PubMed Web of Science ®Google Scholar
• Holler PD, Chlewicki LK, Kranz DM. TCRs with high affinity for foreign pMHC show self-reactivity. Nat Immunol 2002;4:55–62.
   Google Scholar
• Hebeisen M, Baitsch L, Presotto D, SHP-1 phosphatase activity counteracts increased T cell receptor affinity. J Clin Invest 2013;123:1044–1056.
   PubMed Web of Science ®Google Scholar
• Zhong S, Malecek K, Johnson LA, T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy. Proc Natl Acad Sci 2013;110:6973–6978.
   PubMed Web of Science ®Google Scholar
• Cheever MA, Allison JP, Ferris AS, The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009;15:5323–5337.
   PubMed Web of Science ®Google Scholar
• Kumari S, Wälchli S, Fallang L-E, Alloreactive cytotoxic T cells provide means to decipher the immunopeptidome and reveal a plethora of tumor-associated self-epitopes. Proc Natl Acad Sci 2014;111:403–408.
   Google Scholar
• Robbins PF, Lu Y-C, El-Gamil M, Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med 2013;19:747–752.
   PubMed Web of Science ®Google Scholar
• Beard RE, Abate-Daga D, Rosati SF, Gene expression profiling using nanostring digital RNA counting to identify potential target antigens for melanoma immunotherapy. Clin Cancer Res 2013;19:4941–4950.
   PubMed Web of Science ®Google Scholar
• Roesli C, Borgia B, Schliemann C, Comparative analysis of the membrane proteome of closely related metastatic and nonmetastatic tumor cells. Cancer Res 2009;69:5406–5414.
   PubMed Web of Science ®Google Scholar
• Dumont B, Castronovo V, Peulen O, Differential proteomic analysis of a human breast tumor and its matched bone metastasis identifies cell membrane and extracellular proteins associated with bone metastasis. J Proteome Res 2012;11:2247–2260.
   PubMed Web of Science ®Google Scholar
• Bledi Y, Inberg A, Linial M. PROCEED: a proteomic method for analysing plasma membrane proteins in living mammalian cells. Brief Funct Genomic Proteomic 2003;2:254–265.
   Google Scholar
• Olaya-Abril A, Jiménez-Munguía I, Gómez-Gascón L, Rodríguez-Ortega MJ. Surfomics: shaving live organisms for a fast proteomic identification of surface proteins. J Proteomics 2014;97:164–176.
   Google Scholar
• Staquicini FI, Sidman RL, Arap W, Pasqualini R. Phage display technology for stem cell delivery and systemic therapy. Adv Drug Deliv Rev 2010;62:1213–1216.
   PubMedGoogle Scholar
• Uhlen M, Oksvold P, Fagerberg L, Towards a knowledge-based human protein atlas. Nat Biotechnol 2010;28:1248–1250.
   PubMed Web of Science ®Google Scholar
• Rust S, Guillard S, Sachsenmeier K, Combining phenotypic and proteomic approaches to identify membrane targets in a “triple negative” breast cancer cell type. Mol Cancer 2013;12:11.
   PubMed Web of Science ®Google Scholar
• Almendro V, Marusyk A, Polyak K. Cellular Heterogeneity and Molecular Evolution in Cancer. Annu Rev Pathol Mech Dis 2013;8:277–302.
   PubMed Web of Science ®Google Scholar
• Gerlinger M, Rowan AJ, Horswell S, Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366:883–892.
   PubMed Web of Science ®Google Scholar
• Meacham CE, Morrison SJ. Tumour heterogeneity and cancer cell plasticity. Nature 2013;501:328–337.
   PubMed Web of Science ®Google Scholar
• Junttila MR, de Sauvage FJ. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 2013;501:346–354.
   PubMed Web of Science ®Google Scholar
• Klein CA. Selection and adaptation during metastatic cancer progression. Nature 2013;501:365–372.
   PubMed Web of Science ®Google Scholar
• Haso W, Lee DW, Shah NN, Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood 2012;121:1165–1174.
   Google Scholar
• Witte MA de, Jorritsma A, Kaiser A, Requirements for effective antitumor responses of TCR transduced T cells. J Immunol 2008;181:5128–1536.
   Google Scholar
• Aptsiauri N, Cabrera T, Garcia-Lora A, Garrido F. Cancer immune escape: implications for immunotherapy, Granada, Spain, October 3–5, 2011. Cancer Immunol Immunother 2012;61:739–745.
   Google Scholar
• Vesely MD, Schreiber RD. Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy. Ann N Y Acad Sci 2013;1284:1–5.
   PubMed Web of Science ®Google Scholar
• Grada Z, Hegde M, Byrd T, TanCAR: a novel bispecific chimeric antigen receptor for cancer immunotherapy. Mol Ther Acids 2013;2:e105.
   PubMedGoogle Scholar
• Urbanska K, Lanitis E, Poussin M, A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor. Cancer Res 2012;72:1844–1852.
   PubMed Web of Science ®Google Scholar
• Kudo K, Imai C, Lorenzini P, T lymphocytes expressing a CD16 signaling receptor exert antibody-dependent cancer cell killing. Cancer Res 2014;74:93–103.
   PubMed Web of Science ®Google Scholar
• Hegde M, Corder A, Chow KK, Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma. Mol Ther 2013;21:2087–2101.
   PubMed Web of Science ®Google Scholar
• Corbière V, Chapiro J, Stroobant V, Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases. Cancer Res 2011;71:1253–1262.
   PubMed Web of Science ®Google Scholar
• Chmielewski M, Kopecky C, Hombach AA, Abken H. IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res 2011;71:5697–5706.
   PubMed Web of Science ®Google Scholar
• Braun S, Hepp F, Sommer HL, Pantel K. Tumor–antigen heterogeneity of disseminated breast cancer cells: Implications for immunotherapy of minimal residual disease. Int J Cancer 1999;84:1–5.
   PubMedGoogle Scholar
• Hodi FS, O'Day SJ, McDermott DF, Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711–723.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Tykodi SS, Chow LQ, Safety and activity of anti–PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455–2465.
   PubMed Web of Science ®Google Scholar
• John LB, Devaud C, Duong CPM, Anti-PD-1 antibody therapy potently enhances the eradication of established tumors By gene-modified T cells. Clin Cancer Res 2013;19:5636–5646.
   PubMed Web of Science ®Google Scholar
• Dao T, Yan S, Veomett N, Targeting the intracellular WT1 oncogene product with a therapeutic human antibody. Sci Transl Med 2013;5:176ra33–176ra33.
   PubMed Web of Science ®Google Scholar
• Jain R, Rawat A, Verma B, Antitumor activity of a monoclonal antibody targeting major histocompatibility complex class I–Her2 peptide complexes. J Natl Cancer Inst 2013;105:202–218.
   Google Scholar
• Cobbold M, De La Pena H, Norris A, MHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemia. Sci Transl Med 2013;5:203ra125–203ra125.
   PubMed Web of Science ®Google Scholar
• Cameron BJ, Gerry AB, Dukes J, Identification of a titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci Transl Med 2013;5:197ra103–197ra103.
   PubMed Web of Science ®Google Scholar
• Chicaybam L, Laino Sodré A, Bonamino M. Chimeric antigen receptors in cancer immuno-gene therapy: current status and future directions. Int Rev Immunol 2011;30:294–311.
   PubMed Web of Science ®Google Scholar
• Wilkie S, Schalkwyk MCI, Hobbs S, Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. J Clin Immunol 2012;32:1059–1070.
   PubMed Web of Science ®Google Scholar
• Kloss CC, Condomines M, Cartellieri M, Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol 2013;31:71–75.
   PubMed Web of Science ®Google Scholar
• Kershaw MH, Teng MWL, Smyth MJ, Darcy PK. Supernatural T cells: genetic modification of T cells for cancer therapy. Nat Rev Immunol 2005;5:928–940.
   PubMed Web of Science ®Google Scholar
• Fedorov VD, Themeli M, Sadelain M. PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci Transl Med 2013;5:215ra172–215ra172.
   PubMed Web of Science ®Google Scholar
• Lamers CH, Sleijfer S, van Steenbergen S, Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol Ther 2013;21:904–912.
   PubMed Web of Science ®Google Scholar
• Lanitis E, Poussin M, Klattenhoff AW, Chimeric antigen receptor T cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo. Cancer Immunol Res [Internet] 2013 [cited 2013 Apr 11]; Available from: http://cancerimmunolres. aacrjournals.org/cgi/doi/10.1158/2326-6066.CIR-13-0008
   Google Scholar
• Chicaybam L, Sodre AL, Curzio BA, Bonamino MH. An efficient low cost method for gene transfer to T lymphocytes. PLoS ONE 2013;8:e60298.
   PubMedGoogle Scholar
• Hörner M, Weber W. Molecular switches in animal cells. FEBS Lett 2012;586:2084–2096.
   Google Scholar
• Schamel WW, Reth M. Synthetic immune signaling. Curr Opin Biotechnol 2012;23:780–784.
   Google Scholar
• Siuti P, Yazbek J, Lu TK. Synthetic circuits integrating logic and memory in living cells. Nat Biotechnol 2013;31:448–452.
   Google Scholar
• Chen YY, Jensen MC, Smolke CD. Genetic control of mammalian T-cell proliferation with synthetic RNA regulatory systems. Proc Natl Acad Sci 2010;107:8531–8536.
   PubMedGoogle Scholar
• Fábián Á, Vereb G, Szöllősi J. The hitchhikers guide to cancer stem cell theory: Markers, pathways and therapy. Cytometry A 2013;83A:62–71.
   Google Scholar
• Perosa F, Favoino E, Caragnano MA, CD20: a target antigen for immunotherapy of autoimmune diseases. Autoimmun Rev 2005;4:526–531.
   PubMed Web of Science ®Google Scholar
• Beers SA, Chan CHT, French RR, CD20 as a target for therapeutic type I and II monoclonal antibodies. Semin Hematol 2010;47:107–114.
   PubMed Web of Science ®Google Scholar
• Schmidt P, Kopecky C, Hombach A, Eradication of melanomas by targeted elimination of a minor subset of tumor cells. Proc Natl Acad Sci 2011;108:2474–2479.
   PubMed Web of Science ®Google Scholar
• Somasundaram R, Villanueva J, Herlyn M. Will engineered T cells expressing CD20 scFv eradicate melanoma? Mol Ther 2011;19:638–640.
   Google Scholar
• Pinc A, Somasundaram R, Wagner C, Targeting CD20 in melanoma patients at high risk of disease recurrence. Mol Ther 2012;20:1056–1062.
   Google Scholar
• Hosen N, Park CY, Tatsumi N, CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia. Proc Natl Acad Sci 2007;104:11008–11013.
   PubMed Web of Science ®Google Scholar
• Janssen JJWM, Deenik W, Smolders KGM, Residual normal stem cells can be detected in newly diagnosed chronic myeloid leukemia patients by a new flow cytometric approach and predict for optimal response to imatinib. Leukemia 2011;26:977–984.
   Google Scholar
• Paraguassú-Braga FH, Alves AP, Santos IM, An Ectopic stromal implant model for hematopoietic reconstitution and in vivo evaluation of bone marrow niches. Cell Transplant 2012;21:2677–2688.
   Google Scholar
• Paraguassú-Braga FH, Borojevic R, Bouzas LF, Bone marrow stroma inhibits proliferation and apoptosis in leukemic cells through gap junction-mediated cell communication. Cell Death Differ 2003;10:1101–1108.
   PubMed Web of Science ®Google Scholar
• Valent P, Bonnet D, De Maria R, Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer 2012;12:767–775.
   PubMed Web of Science ®Google Scholar
• Theocharides APA, Jin L, Cheng P-Y, Disruption of SIRPα signaling in macrophages eliminates human acute myeloid leukemia stem cells in xenografts. J Exp Med 2012;209:1883–1899.
   PubMed Web of Science ®Google Scholar
• Siolas D, Hannon GJ. Patient derived tumor xenografts: transforming clinical samples into mouse models. Cancer Res 2013;73:5315–5319.
   PubMed Web of Science ®Google Scholar
• Cirri P, Chiarugi P. Cancer-associated-fibroblasts and tumour cells: a diabolic liaison driving cancer progression. Cancer Metastasis Rev 2011;31:195–208.
   Google Scholar
• Garin-Chesa P, Old LJ, Rettig WJ. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci 1990;87:7235–7239.
   PubMed Web of Science ®Google Scholar
• Loeffler M. Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J Clin Invest 2006;116:1955–1962.
   PubMed Web of Science ®Google Scholar
• Mertens JC, Fingas CD, Christensen JD, Therapeutic effects of deleting cancer-associated fibroblasts in cholangiocarcinoma. Cancer Res 2012;73:897–907.
   Google Scholar
• Tran E, Chinnasamy D, Yu Z, Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia. J Exp Med 2013;210:1125–1135.
   PubMed Web of Science ®Google Scholar
• Lunardi S, Muschel RJ, Brunner TB. The stromal compartments in pancreatic cancer: are there any therapeutic targets? Cancer Lett 2014;343:147–155.
   PubMed Web of Science ®Google Scholar
• Wang W, Ma Y, Li J, Specificity redirection by CAR with human VEGFR-1 affinity endows T lymphocytes with tumor-killing ability and anti-angiogenic potency. Gene Ther 2013;20:970–978.
   PubMed Web of Science ®Google Scholar
• Brescia P, Ortensi B, Fornasari L, CD133 is essential for glioblastoma stem cell maintenance. STEM CELLS 2013;31:857–869.
   Google Scholar
• Emlet DR, Gupta P, Holgado-Madruga M, Targeting a glioblastoma cancer stem-cell population defined by EGF receptor variant III. Cancer Res 2013;74:1238–1249.
   Google Scholar
• Campoli MR, Chang C-C, Kageshita T, Human high molecular weight-melanoma-associated antigen (HMW-MAA): a melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance. Crit Rev Immunol 2004;24:267–296.
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay P, Chakraborty S, Ponnusamy MP, Mucins in the pathogenesis of breast cancer: implications in diagnosis, prognosis and therapy. Biochim Biophys Acta BBA—Rev Cancer 2011;1815:224–240.
   PubMed Web of Science ®Google Scholar